Marketing: Page 2

Rising insulin prices drive jump in diabetes treatment costs: report

Higher insulin spending accounted for nearly half of a $6,000 jump in per-person spending for Type 1 diabetes care between 2012 and 2016.

By Les Masterson • Jan. 23, 2019

Walgreens pays $270M to settle Medicaid fraud allegations

For years, the U.S. government alleges, the pharmacy giant routinely submitted false data to improperly secure federal reimbursement for insulin pens not needed by patients.

By Suzanne Elvidge • Jan. 23, 2019

FDA approves third biosimilar of Roche's Herceptin

The go-ahead creates yet another threat to one of the Swiss pharma's top-selling franchises.

By Suzanne Elvidge • Jan. 22, 2019

Lilly suspends Lartruvo promotion after Phase 3 failure

A miss on overall survival in the pharma's ANNOUNCE study calls into question the cancer drug's earlier accelerated approval.

By Jacob Bell • Jan. 18, 2019

Sandoz launches EpiPen rival at $250 per two-pack

The much-delayed launch has been a boost for originator Adamis Pharmaceuticals and provides a new competitor to the beleaguered EpiPen.

By Suzanne Elvidge • Jan. 18, 2019

7 biopharma trends to watch in 2019

Intensifying political pressure, surging cancer drug investment and the rise of pharma chief digital officers are among the factors which look set to shape the industry's next 12 months.

By Ned Pagliarulo • Jan. 17, 2019

Hospital drug spend spiked 19% from 2015-17, coalition says

The report, sponsored by hospital and pharmacy groups, is the latest attack in an ongoing battle over who should hold blame for high healthcare costs.

By Rebecca Pifer • Jan. 16, 2019

Allergan, Mohawk tribe ask for Supreme Court review of scrutinized patent case

A controversial deal designed to protect an Allergan top-seller from competition has so far proved for naught, but the two aim to continue their legal fight.

By Ned Pagliarulo • Jan. 16, 2019

Congressional investigation targets Pfizer, Novartis and J&J, among others

The new House Oversight chairman has asked 12 pharmas for pricing info on 18 top drugs, as Congress prepares to further scrutinize the industry.

By Andrew Dunn • Jan. 15, 2019

Louisiana launching 'Netflix model' in Medicaid for hep C drugs

The state is looking for a pharmaceutical partner on a project that will cap state spending for the expensive liver disease treatments.

By Les Masterson • Jan. 14, 2019

NICE turns down Novartis' Aimovig, flagging clinical trial concerns

The most clinically important patients were excluded from studies, the reviewing committee concluded in its draft decision to not recommend U.K. coverage of the migraine drug.

By Andrew Dunn • Jan. 11, 2019

J&J raises prices as Dems introduce bills aimed at lowering drug costs

Drug pricing reform has bipartisan support, but that hasn't stopped pharma from enacting hikes — in part because such moves have been vital to growth.

By Jacob Bell • Jan. 11, 2019

Grassley to zoom in on drug pricing, insurance mergers as Senate panel chair

The new Republican chairman of the Senate Finance Committee laid out his agenda, including allowing cheaper drug imports from Canada.

By David Lim • Jan. 10, 2019

As pharmas revert to regular price hikes, Azar threatens action with 'fighting words'

The Health and Human Services Secretary praised Merck & Co., Gilead Sciences and Amgen by name Wednesday on Twitter before declaring the industry "must stop" raising list prices.

By Andrew Dunn • Jan. 09, 2019

Bluebird proposes installment plan for LentiGlobin gene therapy

The biotech company would receive further payments only if LentiGlobin keeps working, according to a payment idea the company rolled out Tuesday.

By Kristin Jensen

Pharma DTC spending outpaces rest of medical marketing, JAMA study finds

Companies spent $30 billion on medical marketing in 2016, up 60% from two decades ago. Direct-to-consumer spending more than tripled over that time.

By Andrew Dunn • Jan. 07, 2019

Esperion licenses European rights on cholesterol drug for $300M

While Esperion plans to file for approval in the first half of 2019, a long-term CV outcomes study lingers with an expected readout in 2022. 

By Andrew Dunn • Jan. 04, 2019

Drugmakers open new year with price increases on dozens of medicines

Allergan, Biogen and Bristol-Myers were among the companies that raised list prices, suggesting criticism hasn't halted a return to "business as normal" for the industry.

By Ned Pagliarulo • Jan. 02, 2019

Acorda wins FDA nod for Parkinson's drug

An OK for Inbrija may help Acorda rebound from a damaging court ruling that opened the door for generic competition to the biotech's only marketed drug.

By Ned Pagliarulo • Dec. 24, 2018

Our 10 best stories of 2018

Pharma boards, cell therapy, AI and cancer drug ads feature in BioPharma Dive's top articles of the past 12 months.

By Ned Pagliarulo • Dec. 21, 2018

Gene therapy could be cost effective in SMA, but not at $4M

A report from ICER found Novartis' experimental Zolgensma could be more cost-effective than Biogen's Spinraza in treating spinal muscular atrophy.

By Ned Pagliarulo • Dec. 21, 2018

Trump drug ad proposal earns support from insurers, medical groups

Pharma strongly opposes the idea, however, arguing it would spark confusion and paint a misleading picture of what drugs end up costing consumers.

By Ned Pagliarulo • Dec. 19, 2018

Novartis, Pfizer withdraw drug applications in Europe

Novartis pulled canakinumab, with regulators leaning against approval, and Pfizer withdrew its Humira biosimilar.

By Andrew Dunn • Dec. 17, 2018

American leaders' distrust in science a 'dangerous situation,' BIO chair says

John Maraganore, the chair of biotech's largest trade group, said he's concerned the recent controversy over gene-edited babies could trigger knee-jerk reactions.

By Andrew Dunn • Dec. 14, 2018